UP!
|
Type
|
Public NASDAQ: ALKS |
|---|---|
| Industry | Biotechnology |
| Headquarters | Dublin, Ireland |
|
Key people
|
Richard Pops, CEO |
| Revenue |  US$187 Million |
|
Operating income
|
 US$-42.9 Million |
|
Net income
|
US$-39.6 Million |
| Total assets | US$452 Million |
| Total equity | US$392 Million |
|
Number of employees
|
1200 |
| Website | www.alkermes.com |
Alkermes plc is a biopharmaceutical company that focuses on central nervous system (CNS) diseases. The company is the result of a merger in September 2011 between Alkermes, Inc., and Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and manufacturing facilities in Athlone, Ireland, and Wilmington, Ohio.
Alkermes has more than 20 commercial drug products and candidates that address serious and chronic diseases, such as addiction, schizophrenia, diabetes and depression. Among these products, five are primary to the company: risperidone long-acting Injection (generic for Risperdal Consta) for schizophrenia and bipolar 1 disorder, paliperidone palmitate (generic for Invega Sustenna in the U.S., Xeplion in Europe) for schizophrenia, 4-aminopyridine (generic for Ampyra in the U.S., Fampyra in Europe) to improve walking in patients with multiple sclerosis, naltrexone for extended-release injectable suspension (generic for Vivitrol) for alcohol and opioid dependence, and exenatide extended-release for injectable suspension (generic for Bydureon) for the treatment of type 2 diabetes. Bydureon is a once-weekly, extended-release form of the drug, exenatide (Byetta), and was developed through a partnership between Amylin Pharmaceuticals, Alkermes and Eli Lilly. It is approved in Europe and the U.S.
Buprenorphine/samidorphan (ALKS-5461), a κ-opioid receptor antagonist, is a next-generation, novel antidepressant which is under development by Alkermes for treatment-resistant depression.
Olanzapine/samidorphan (ALKS-3831) is an atypical antipsychotic and opioid modulator combination that is under development for the treatment of schizophrenia and bipolar mania.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-10-28 | Future report Set alerts | |
| Q2 2022 | 2022-07-27 | 0.06 | 0.06 |
| Q1 2022 | 2022-04-27 | 0.12 | 0.12 |
| Q4 2021 | 2022-02-16 | 0.23 | 0.23 |
| Q3 2021 | 2021-10-27 | 0.14 | 0.14 |
| Q2 2021 | 2021-07-28 | 0.30 | 0.30 |
| Q1 2021 | 2021-04-28 | 0.11 | 0.11 |
| Q4 2020 | 2021-02-11 | 0.10 | 0.10 |
| Q3 2020 | 2020-10-21 | 0.00 | 0.00 |
| Q2 2020 | 2020-07-29 | 0.06 | -0.19 |
| 2016-06-28 | Reiterated Rating | Leerink Swann | Outperform | $58.00 to $54.00 |
| 2016-06-02 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-06-02 | Reiterated Rating | Credit Suisse | Buy | |
| 2016-06-02 | Reiterated Rating | Credit Suisse Group AG | Buy | |
| 2016-05-26 | Initiated Coverage | Evercore ISI | Buy | $59.00 |
| 2016-05-25 | Reiterated Rating | Leerink Swann | Outperform | $58.00 |
| 2016-05-05 | Initiated Coverage | Cowen and Company | Market Perform | |
| 2016-04-30 | Reiterated Rating | Morgan Stanley | Sell | |
| 2016-04-21 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-03-07 | Reiterated Rating | Credit Suisse | Buy | |
| 2016-02-27 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-02-22 | Lower Price Target | Goldman Sachs | $57.00 to $35.00 | |
| 2016-02-22 | Lower Price Target | Goldman Sachs Group Inc. | $57.00 to $35.00 | |
| 2016-02-16 | Reiterated Rating | Leerink Swann | Outperform | $58.00 |
| 2016-02-08 | Lower Price Target | Citigroup Inc. | Neutral | $36.00 |
| 2016-01-22 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-01-21 | Reiterated Rating | Guggenheim | Hold | |
| 2016-01-21 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-01-21 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $77.00 to $51.00 |
| 2016-01-21 | Downgrade | Morgan Stanley | Overweight to Underweight | $35.00 |
| 2016-01-21 | Downgrade | Cowen and Company | Outperform to Hold | $80.00 to $50.00 |
| 2016-01-21 | Lower Price Target | Leerink Swann | Outperform | $84.00 to $58.00 |
| 2016-01-13 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | |
| 2015-12-03 | Reiterated Rating | Credit Suisse | Outperform | $67.00 to $80.00 |
| 2015-11-06 | Boost Price Target | Leerink Swann | Outperform | $81.00 to $84.00 |
| 2015-10-30 | Boost Price Target | Jefferies Group | $76.00 to $81.00 | |
| 2015-10-30 | Reiterated Rating | Barclays | Buy | $79.00 to $83.00 |
| 2015-10-30 | Reiterated Rating | Barclays PLC | Buy | $79.00 to $83.00 |
| 2015-10-29 | Reiterated Rating | JPMorgan Chase & Co. | Buy | $77.00 |
| 2015-10-29 | Reiterated Rating | Leerink Swann | Outperform | |
| 2015-10-07 | Boost Price Target | Barclays | Overweight | $77.00 to $79.00 |
| 2015-10-06 | Reiterated Rating | Credit Suisse | Buy | |
| 2015-10-06 | Reiterated Rating | Morgan Stanley | Buy | |
| 2015-09-01 | Upgrade | Morgan Stanley | Underweight to Overweight | $61.00 to $85.00 |
| 2015-07-30 | Reiterated Rating | JPMorgan Chase & Co. | Buy | $77.00 |
| 2015-07-29 | Reiterated Rating | Cowen and Company | Buy | $80.00 |
| 2015-07-20 | Boost Price Target | Goldman Sachs | Neutral | $47.00 to $48.00 |
| 2015-06-09 | Initiated Coverage | Guggenheim | Neutral | |
| 2015-05-21 | Initiated Coverage | Barclays | Overweight | $74.00 |
| 2015-05-20 | Initiated Coverage | Credit Suisse | Outperform | |
| 2015-05-12 | Initiated Coverage | Credit Suisse | Outperform | $75.00 to $59.51 |
| 2015-05-09 | Reiterated Rating | Jefferies Group | Buy | $78.00 to $74.00 |
| 2015-05-01 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $77.00 |
| 2015-03-27 | Downgrade | Citigroup Inc. | Buy to Neutral | $83.00 to $71.00 |
| 2015-03-12 | Downgrade | Morgan Stanley | Equal Weight to Underweight | $61.00 |
| 2015-03-10 | Lower Price Target | Jefferies Group | Buy | $80.00 to $78.00 |
| 2015-02-25 | Lower Price Target | Citigroup Inc. | Buy | $85.00 to $83.00 |
| 2015-02-25 | Set Price Target | Bank of America | Sell | $45.00 |
| 2015-02-25 | Set Price Target | Bank of America Corp. | Sell | $45.00 |
| 2015-02-24 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $77.00 |
| 2015-02-09 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
| 2015-01-14 | Boost Price Target | Citigroup Inc. | Buy | $72.00 to $85.00 |
| 2015-01-08 | Boost Price Target | Leerink Swann | Outperform | $66.00 to $75.00 |
| 2015-01-08 | Boost Price Target | Mizuho | Buy | $72.00 to $81.00 |
| 2015-01-06 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
| 2014-12-17 | Reiterated Rating | Citigroup Inc. | Buy | $60.00 to $72.00 |
| 2014-12-08 | Boost Price Target | Credit Suisse | Outperform | $56.00 to $63.00 |
| 2014-08-01 | Lower Price Target | Credit Suisse | $57.00 to $56.00 | |
| 2014-07-31 | Lower Price Target | Mizuho | Buy | $61.00 to $59.00 |
| 2014-05-16 | Initiated Coverage | Jefferies Group | Buy | $53.00 |
| 2014-04-10 | Upgrade | Mizuho | Neutral to Buy | $56.00 to $61.00 |
| 2014-04-09 | Boost Price Target | MKM Partners | Sell | $32.00 to $35.00 |
| 2014-04-08 | Reiterated Rating | Leerink Swann | Outperform | $60.00 to $66.00 |
| 2014-04-02 | Initiated Coverage | Credit Suisse | Outperform | $57.00 |
| 2014-02-28 | Reiterated | UBS | Neutral | $42 to $53 |
| 2014-02-28 | Boost Price Target | MKM Partners | Sell | $26.00 to $32.00 |
| 2014-02-28 | Boost Price Target | Mizuho | Neutral | $33.00 to $56.00 |
| 2014-01-24 | Boost Price Target | Leerink Swann | $46.00 to $58.00 | |
| 2013-12-16 | Boost Price Target | Leerink Swann | $42.00 to $46.00 | |
| 2013-12-05 | Downgrade | UBS | Buy to Neutral | $37 to $42 |
| 2013-11-01 | Boost Price Target | Mizuho | Neutral | $30.00 to $33.00 |
| 2013-10-30 | Initiated Coverage | FBR & Co. | Market Perform | $31.00 |
| 2013-10-17 | Reiterated Rating | Citigroup Inc. | Focus List | $38.00 to $43.00 |
| 2013-10-01 | Downgrade | Morgan Stanley | Overweight to Equal Weight | |
| 2013-05-24 | Reiterated | UBS | Buy | $32 to $37 |
| 2013-05-24 | Downgrade | MKM Partners | Neutral to Sell | |
| 2013-04-18 | Downgrade | Mizuho | Buy to Neutral | $30 to $26 |
| 2013-04-17 | Reiterated | MKM Partners | Neutral | $23 to $25 |
| 2013-01-23 | Downgrade | MKM Partners | Buy to Neutral | |
| 2012-11-16 | Initiated | Mizuho | Buy | $27 |
| 2012-01-25 | Upgrade | MKM Partners | Neutral to Buy | $19 to $20 |
| 2011-08-23 | Upgrade | UBS | Neutral to Buy | $20.50 to $21 |
| 2011-07-08 | Reiterated | UBS | Neutral | $19 to $20.50 |
| 2011-06-07 | Reiterated | UBS | Neutral | $16.50 to $19 |
| 2011-05-10 | Reiterated | UBS | Neutral | $14.50 to $16.50 |
| 2010-10-20 | Downgrade | Caris & Company | Above Average to Average | $16 to $10 |
| 2016-06-28 | Reiterated Rating | Leerink Swann | Outperform | $58.00 to $54.00 |
| 2016-06-02 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-06-02 | Reiterated Rating | Credit Suisse | Buy | |
| 2016-06-02 | Reiterated Rating | Credit Suisse Group AG | Buy | |
| 2016-05-26 | Initiated Coverage | Evercore ISI | Buy | $59.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ALKS 209 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Vanguard Group, Inc | 18.11M |
| BlackRock Inc. | 15.49M |
| Sarissa Capital Management LP | 14.04M |
| WELLINGTON MANAGEMENT CO LLP | 6.72M |
| STATE STREET CORP | 6.47M |
| JOHNSTON ASSET MANAGEMENT CORP | 5.73M |
| RENAISSANCE TECHNOLOGIES LLC | 5.56M |
| PRIMECAP MANAGEMENT CO/CA/ | 5.35M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.69M |
| CITADEL ADVISORS LLC | 4.25M |
| BlackRock Institutional Trust Company, N.A. | 4.07M |
| ARMISTICE CAPITAL, LLC | 3.79M |
| BlackRock Fund Advisors | 3.72M |
| GEODE CAPITAL MANAGEMENT, LLC | 2.95M |
| GOLDMAN SACHS GROUP INC | 2.28M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| POPS RICHARD F Director and CEO, Alkermes plc | 0.46% (666352) | ALKS / EPZM / NBIX / XLRN / |
| LANDINE MICHAEL J SVP, Corp Dev., Alkermes, Inc. | 0.12% (172644) | ALKS / KOPN / |
| Cooke Shane President, Alkermes plc | 0.06% (84872) | ALKS / PRTA / |
| FRATES JAMES M SVP & CFO, Alkermes plc | 0.06% (84340) | ALKS / SAGE / |
| Ehrich Elliot SVP, R&D & CMO, Alkermes, Inc. | 0.04% (57056) | ALKS / |
| ANSTICE DAVID W | 0.04% (55000) | ALKS / |
| Stejbach Mark Chief Commercial Officer | 0.04% (51065) | ALKS / FLXN / TNGN / |
| BIBERSTEIN KATHRYN L SVP, GC, Secretary, Alks, Inc. | 0.03% (40200) | ALKS / |
| Gaffin David Joseph SVP, CLO, Alkermes, Inc. | 0.02% (36363) | ALKS / |
| Brown Iain Michael VP, Finance & CAO | 0.02% (21895) | ALKS / |
| Pugh Gordon G SVP, COO & CRO, Alkermes, Inc. | 0.01% (20587) | ALKS / |
| BLOOM FLOYD E | 0.01% (20000) | ALKS / |
UM